Aidence
AI-powered clinical applications for the lung cancer pathway
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Machine Learning
- SaaS
- MedTech
- De Weteringschans, Amsterdam, Netherlands
Jump to section
Company mission
To provide AI that empowers healthcare and pharmaceutical professionals to deliver faster, more precise diagnostics and treatments.
Our take
The medical technology market is expected to continue its growth due to innovative technological developments, the increasing pace of population ageing, chronic diseases, and trust in medical devices. And advancements in AI and robotic solutions, cloud-based software and healthcare apps, are likely to boost industry growth in the future.
Radiologists agree that AI is necessary to compensate for the increase in medical images they need to assess. Without AI, the demand for scans would outgrow the human ability to review them timely and accurately. Aidence provides an AI solution for lung nodule detection and management, which helps improve lung cancer prognosis by detecting, measuring, classifying and tracking the growth of pulmonary nodules on patients' chest CT scans.
Aidence was acquired by US radiology firm RadNet in 2022. Its future goals include expanding its products to detect larger masses on chest CTs and using the data collected from scans to provide further insights into the effectiveness of lung cancer treatments.
Steph
Company Specialist at Welcome to the Jungle
Funding (last 2 of 3 rounds)
Mar 2020
$2.1m
GRANT
Feb 2019
$10.8m
SERIES A
Total funding: $15.4m
This company has top investors